ClinicalTrials.gg
CompletedNCT04328727REACTSUpdated Jan 13, 2026Results posted

Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia

A Phase 2 interventional study of eltrombopag and rabbit anti-thymocyte globulin (r-ATG) in Severe Aplastic Anemia (SAA), sponsored by Novartis Pharmaceuticals. Completed at 12 sites in 4 countries. Open to participants aged 6 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-01-13.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
6 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing eltrombopag in Anemia, Aplastic — 3 open to participants now, 3 under way, 1 of them phase 3. eltrombopag · Anemia, Aplastic.

Enrollment
9th of 17
36 · median 36
Started
2020
with 2 others
Phase 2
11 of 17
1 open now
Registered
14th of 17
by date
Lead sponsor
6 of 17
Novartis Pharmaceuticals

Among the 17 studies testing eltrombopag in Anemia, Aplastic, this one is the 9th largest by enrollment, is one of 3 that started in 2020, is one of 11 in phase 2, and was the 14th registered.

Anemia, Aplastic

372 studies on the registry are indexed under Anemia, Aplastic; 99 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

3 of the 17 studies testing eltrombopag in Anemia, Aplastic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About eltrombopag

eltrombopag: first FDA approval 2008 (PROMACTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 59 Anemia, Aplastic studies recruiting now, 21 (36%) set no upper age limit and 30 (51%) stop at 75 or younger; 38 take children under 18; 5 take healthy volunteers.

This study: 6 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing eltrombopag in Anemia, Aplastic, or all of them as a file.
02

Study summary

This study was designed to evaluate the efficacy and safety of eltrombopag when added to r-ATG and CsA in treatment naive East-Asian adult and pediatric patients with severe aplastic anemia (SAA).

Read the detailed description

This was a non-randomized, open label, single arm, multi-center, Phase II study to evaluate the efficacy and safety of eltrombopag in combination with immunosuppressive therapy (IST) regimen of r-ATG + CsA in East-Asian patients with severe aplatsic anemia who had not received prior IST.

Eligible participants were enrolled into the study and received eltrombopag (from Day 1 to Week 26) concomitantly with r-ATG (on Days 1-5) and CsA (from Day 1 to Week 26) in the core treatment part.

Participants who were assessed as responders (meeting complete (CR) or partial (PR) response criteria) at Week 26 were eligible for the extension part of the study and continued treatment with eltrombopag and CsA after Week 26 up to Week 52. During the extension part, eltrombopag treatment was provided up to Week 52. CsA was maintained or tapered at the investigator's discretion according to local practice, with a total duration of at least 2 years (18 months after Week 26). There was a 30 days after end of treatment safety follow-up at the end of the extension part.

All participants were offered to enter the long term follow-up after the discontinuation of eltrombopag, with yearly efficacy and clonal evolution assessments up to Year 3 (Week 156).

03

Conditions studied

  • Severe Aplastic Anemia (SAA)

Browse trials for

Keywords

  • Treatment naïve severe aplastic anemia
  • SAA
  • eltrombopag
  • ETB115
  • immunosuppressive therapy
  • rabbit anti-thymocyte globulin
  • r-ATG
  • cyclosporine A
  • CsA
  • East-Asian patients
04

Who can participate

Ages eligible
6 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written study and (where applicable) assent from the subject, parent, or guardian must be obtained prior to participation in the study.
  • Subjects of East Asian ethnicity aged ≥ 6 years old at the time of written informed consent and assent form (if applicable).
  • SAA characterized by:
  • Bone marrow cellularity \< 25%, or 25-50% with \< 30% residual hematopoietic cells and pancytopenia, with at least two of the following parameters in peripheral blood:
  • \< 0.5×109/L
  • count \< 20×109/L
  • Absolute reticulocyte count \< 20×109/L
  • not suitable or available as a treatment option (determined as per local practices or national guidelines), or has been refused by subject.

Exclusion criteria

Exclusion Criteria:

  • Prior IST with any ATG/ALG , alemtuzumab, high dose cyclophosphamide (≥ 45 mg/kg/day), CsA within 6 months, or prior thrombopoietin receptor agonists.
  • (ECOG) performance status (age ≥ 16 years) >2, or Lansky performance status (age \< 16 years) \<50.
  • Prior and/or active medical history of:
  • Known underlying congenital/inherited bone marrow failure or aplastic anemia (e.g.,such as but not limited to Fanconi anemia, congenital dyskeratosis, congenital amegakaryocytic thrombocytopenia, or Shwachman-Diamond Syndrome)
  • Symptomatic paroxysmal nocturnal hemoglobinuria (PNH) and/or PNH clones >50% of polymorphonuclear neutrophil (PMN) or RBC at time of enrollment
  • Myelodysplastic syndrome (MDS)
  • Any cytogenetic abnormalities on karyotyping or FISH within 30 days of study enrollment (an evaluable karyotyping with at least 10 metaphases is mandatory for eligibility)
  • Other known or suspected underlying primary immunodeficiency
  • Any concomitant that have not fully recovered from treatment or have not been disease-free for 5 years
  • (AST) or alanine aminotransferase (ALT) >3 times the (ULN).
  • Creatinine ≥ 2.5×local ULN
  • Past medical history of thromboembolism within 6 months, and/or prior or current antiphospholipid antibody syndrome (APS).
  • Presence of clinically active uncontrolled significant (of such severity that it would preclude the subject's ability to consent, be compliant with study procedures, tolerate protocol therapy) infection, including bacterial, fungal, mycobacterial, parasitic or viral infection, or any concurrent condition that, in the Investigator's opinion, would jeopardize the safety of the subject or compliance with the protocol
  • Any severe and/or uncontrolled medical conditions which could cause unacceptable safety risks or compromise compliance with the protocol, such as:
  • Known hepatocellular disease (e.g. active hepatitis or cirrhosis)
  • Impairment of gastrointestinal (GI) function or gastrointestinal disease that may significantly alter the absorption of study treatment (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome)
  • Active skin, mucosa, ocular or GI disorders of Grade > 1
  • Presence of surface antigen (HBsAg) or positive antibody test result at screening. A positive serology for Hepatitis B (HB) is considered as a positive test for HBsAg. In addition, if serology is negative for HBsAg but hepatitis B core antibody (HBcAb) is positive (regardless of hepatitis B surface antibody (HBsAb) status), a hepatitis B virus (HBV) DNA test will be performed and if positive the patient will be excluded.
  • Cardiac disorder (subjects with congestive heart disease of (NYHA) functional classification Grade II/III/IV (for pediatric subjects, refer to the Grade II/III/IV of Modified ross heart failure classification for Children) should not be enrolled; subjects with NYHA Grade II due to cardiac disorder should not be enrolled but those with NYHA Grade II due to aplastic anemia (AA) may be enrolled.), arrhythmia with a risk of thrombosis (e.g. atrial fibrillation), pulmonary hypertension, or uncontrolled hypertension (>180/100 mmHg).
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    eltrombopag

    Participants received eltrombopag in combination with r-ATG and CsA. * Eltrombopag was administered orally once daily with initial doses of 75mg/day for ≥ 12 years old and 37.5 mg/day for participants between ≥ 6 and \< 12 years. Doses could be adjusted based on platelet count * r-ATG was administered intravenously at a dose of 2.5 to 3.5 mg/kg/day on Days 1-5 * CsA was administered orally every 12 h at a starting dose of 3-6 mg/kg/day

    Drug: eltrombopag · Drug: rabbit anti-thymocyte globulin (r-ATG) · Drug: cyclosporine A (CsA)

Interventions

06

What researchers measure

Primary outcomes

  1. Complete Response (CR) Rate at Week 26

    Complete response rate was defined as percentage of patients achieving complete response (CR). Complete response was defined as subjects meeting all the three criteria on two consecutive serial blood count measurements at least one week apart but not more than four weeks apart: * Absolute neutrophil count \> 1.0 ×10\^9/L * Platelet count \> 100 ×10\^9/L * Hemoglobin \> 100 g/L The participants who discontinued from the trial before Week 26 and those that received blood products prior to response assessment (7 days prior for platelet transfusions, 14 days for RBC transfusion and 21 days for growth factors) were treated as non-responders.

    Time frame: Week 26 (6 months after starting study treatment)

Secondary outcomes

  1. Complete Response (CR) Rate

    Complete response rate was defined as percentage of patients achieving complete response (CR). Complete response was defined as subjects meeting all the three criteria on two consecutive serial blood count measurements at least one week apart but not more than four weeks apart: * Absolute neutrophil count \> 1.0 ×10\^9/L * Platelet count \> 100 ×10\^9/L * Hemoglobin \> 100 g/L The participants who discontinued from the trial before Week 26 and those that received blood products prior to response assessment (7 days prior for platelet transfusions, 14 days for RBC transfusion and 21 days for growth factors) were treated as non-responders.

    Time frame: Week 13 (3 months), Week 52 (12 months) and yearly after up to 3 years

  2. Overall Response (ORR) Rate

    Overall response rate was defined as percentage of patients achieving complete response (CR) or partial response (PR). Partial response (PR) was defined as blood counts no longer meeting the standard criteria for severe pancytopenia in SAA, equivalent to at least 2 of the 3 criteria below, but not sufficient for a CR: * Absolute neutrophil count ≥ 0.5 × 10\^9/L * Platelet count ≥ 20 × 10\^9/L * Reticulocyte count ≥ 20 × 10\^9/L Complete response (CR) was defined as subjects meeting all the three criteria on two consecutive serial blood count measurements at least one week apart but not more than four weeks apart: * Absolute neutrophil count \> 1.0 ×10\^9/L * Platelet count \> 100 ×10\^9/L * Hemoglobin \> 100 g/L

    Time frame: Week 13 (3 months), 26 weeks (6 months), 52 weeks and yearly after up to 3 years

  3. Duration of Complete Response

    Duration of response was derived as the time from first documented and confirmed complete response (CR) until the time of relapse or death, whichever occurred first. Duration of response was estimated using Kaplan-Meier method. Clinical relapse was considered as the occurrence of any of the following events in a participant who had achieved a hematological response (CR) but had subsequently lost response (not explained by any other independent concomitant medical conditions) in one blood count measurements: * Meeting again the criteria for SAA * Requirement for transfusion again for subjects who had been transfusion independent * Decrease in any of the peripheral blood counts to absolute neutrophil count \< 0.5 x10\^9/L or platelets \< 20 x10\^9/L.

    Time frame: Up to aproximately 3 years

  4. Duration of Overall Response

    Duration of response was derived as the time from first documented and confirmed response (either CR or PR) until the time of relapse or death, whichever occurred first. Duration of response was estimated using Kaplan-Meier method. Clinical relapse was considered as the occurrence of any of the following events in a participant who had achieved a hematological response (CR or PR) but had subsequently lost response (not explained by any other independent concomitant medical conditions) in one blood count measurements: * Meeting again the criteria for SAA * Requirement for transfusion again for subjects who had been transfusion independent * Decrease in any of the peripheral blood counts to absolute neutrophil count \< 0.5 x10\^9/L or platelets \< 20 x10\^9/L.

    Time frame: Up to aproximately 3 years

  5. Overall Survival (OS)

    OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. If a subject was not known to have died, survival was censored at the date of last contact. The distribution function of OS was estimated using the Kaplan- Meier method.

    Time frame: Up to approximately 3 years

  6. Overall Survival (OS) Rate

    OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. The OS rate is the estimated probability that a patient will remain event-free up to the specified time point and was obtained from the Kaplan-Meier survival estimates. If a subject was not known to have died, survival was censored at the date of last contact.

    Time frame: Week 26, Week 52 and yearly after up to 3 years

  7. Red Blood Cells (RBC) and Platelet Transfusion-free Interval Before Week 13 and 26

    Transfusion-free interval was defined as the time from most recent RBC/platelet transfusion preceding response assessment to the date of response assessment.

    Time frame: Week 13, 26

  8. Percentage of Participants Who Become RBC Transfusion Independent

    Transfusion independent participants were defined as those participants who were transfusion dependent at baseline but became transfusion free for a period of ≥ 8 weeks post-baseline for RBCs.

    Time frame: From date of first dose to approximately 3 years

  9. Percentage of Participants Who Become Platelet Transfusion Independent

    Transfusion independent participants were defined as those participants who were transfusion dependent at baseline but became transfusion free for a period of ≥ 4 weeks post-baseline for platelets.

    Time frame: From date of first dose to approximately 3 years

  10. Time From the Date of First Dose of Investigational Treatment to the Date of First Occurrence of Any Clonal Evolution Events

    Clonal evolution events were assessed by karyotyping (G-banding) and FISH (Fluorescence in situ hybridization) targeting abnormalities including, but not restricted to chromosome 3q del,5q del, monosomy 7, trisomy 8 and those associated with SAA (Severe aplastic anemia), MDS (Myelodysplastic syndrome), AML (Acute myeloid leukemia). Time to clonal evolution was to be estimated using the Kaplan-Meier method.

    Time frame: From date of first dose to approximately 3 years

  11. Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: AUClast

    AUClast is the area under the curve from time zero to the last measurable concentration sampling time. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.

    Time frame: Pre-dose, and 2, 4, 6, 8 and 24 hours post-dose on Day 14 after initial dose

  12. Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: AUCtau

    AUCtau is area under the curve calculated to the end of a dosing interval (tau) at steady-state Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.

    Time frame: Pre-dose, and 2, 4, 6, 8 and 24 hours post-dose on Day 14 after initial dose

  13. Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: Ctrough

    Cthrough is the pre-dose concentration at the end of dose interval. Blood samples were collected to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach. Eltrombopag was administered orally once daily with initial doses of 75mg/day for ≥ 12 years old and 37.5 mg/day for participants between ≥ 6 and \< 12 years. Doses could be adjusted based on platelet count every 2 weeks by decreasing it by 25 mg/day (12.5 mg/day, for participants below 12 years old) if the platelet count was above 200×10\^9/L. or interrupted if platelet count rose above 400×10\^9/L. In partial response participants dose could be restarted or increased to that before the decrease if platelet counts \< 30 x10\^9/L, Hb\< 90 g/L, ANC\< 0.5 x 10\^9/L or participant needed transfusion. In complete response participants dose could be restarted or increased to that before decrease if blood counts dropped to not meet CR criteria.

    Time frame: Pre-dose on day 15 after initation of eltrombopag and and pre-dose on the 15th day after each new dose up to week 26

  14. Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: Cmax

    Cmax is the The maximum (peak) observed plasma drug concentration after dose administration. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.

    Time frame: Pre-dose, and 2, 4, 6, 8 and 24 hours post-dose on Day 14 after initial dose

  15. Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: Tmax

    Tmax is the time to reach maximum (peak) plasma drug concentration after dose administration. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.

    Time frame: Pre-dose, and 2, 4, 6, 8 and 24 hours post-dose on Day 14 after initial dose

  16. Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: CLss/F

    CLss/F is Apparent systemic (or total body) clearance at steady state from plasma. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.

    Time frame: Pre-dose, and 2, 4, 6, 8 and 24 hours post-dose on Day 14 after initial dose

07

Results

Posted Jul 17, 2025

Participant flow

Participants were enrolled at 12 sites in 4 different countries

Participant flow — Overall Study
MilestoneEltrombopag
Started36
Started extension part28
Started long term follow up34
Completed28
Not completed8
Withdrew: Guardian decision1
Withdrew: Participant decision4
Withdrew: Death3

Outcome measures

PrimaryComplete Response (CR) Rate at Week 26

Complete response rate was defined as percentage of patients achieving complete response (CR). Complete response was defined as subjects meeting all the three criteria on two consecutive serial blood count measurements at least one week apart but not more than four weeks apart: * Absolute neutrophil count \> 1.0 ×10\^9/L * Platelet count \> 100 ×10\^9/L * Hemoglobin \> 100 g/L The participants who discontinued from the trial before Week 26 and those that received blood products prior to response assessment (7 days prior for platelet transfusions, 14 days for RBC transfusion and 21 days for growth factors) were treated as non-responders.

Time frame:
Week 26 (6 months after starting study treatment)
Reported as:
Number · percentage of participants
Complete Response (CR) Rate at Week 26
percentage of participantsEltrombopag
All participants16.7 (6.4 to 32.8)
< 18 years25 (3.2 to 65.1)
18-64 years15.4 (4.4 to 34.9)
≥ 65 years0 (0.0 to 84.2)
SecondaryComplete Response (CR) Rate

Complete response rate was defined as percentage of patients achieving complete response (CR). Complete response was defined as subjects meeting all the three criteria on two consecutive serial blood count measurements at least one week apart but not more than four weeks apart: * Absolute neutrophil count \> 1.0 ×10\^9/L * Platelet count \> 100 ×10\^9/L * Hemoglobin \> 100 g/L The participants who discontinued from the trial before Week 26 and those that received blood products prior to response assessment (7 days prior for platelet transfusions, 14 days for RBC transfusion and 21 days for growth factors) were treated as non-responders.

Time frame:
Week 13 (3 months), Week 52 (12 months) and yearly after up to 3 years
Reported as:
Number · percentage of participants
Complete Response (CR) Rate
percentage of participantsEltrombopag
Week 135.6 (0.7 to 18.7)
Week 5230.6 (16.3 to 48.1)
Year 230.6 (16.3 to 48.1)
Year 330.6 (16.3 to 48.1)
SecondaryOverall Response (ORR) Rate

Overall response rate was defined as percentage of patients achieving complete response (CR) or partial response (PR). Partial response (PR) was defined as blood counts no longer meeting the standard criteria for severe pancytopenia in SAA, equivalent to at least 2 of the 3 criteria below, but not sufficient for a CR: * Absolute neutrophil count ≥ 0.5 × 10\^9/L * Platelet count ≥ 20 × 10\^9/L * Reticulocyte count ≥ 20 × 10\^9/L Complete response (CR) was defined as subjects meeting all the three criteria on two consecutive serial blood count measurements at least one week apart but not more than four weeks apart: * Absolute neutrophil count \> 1.0 ×10\^9/L * Platelet count \> 100 ×10\^9/L * Hemoglobin \> 100 g/L

Time frame:
Week 13 (3 months), 26 weeks (6 months), 52 weeks and yearly after up to 3 years
Reported as:
Number · percentage of participants
Overall Response (ORR) Rate
percentage of participantsEltrombopag
Week 1366.7 (49.0 to 81.4)
Week 2677.8 (60.8 to 89.9)
Week 5266.7 (49.0 to 81.4)
Year 250.0 (32.9 to 67.1)
Year 341.7 (25.5 to 59.2)
SecondaryDuration of Complete Response

Duration of response was derived as the time from first documented and confirmed complete response (CR) until the time of relapse or death, whichever occurred first. Duration of response was estimated using Kaplan-Meier method. Clinical relapse was considered as the occurrence of any of the following events in a participant who had achieved a hematological response (CR) but had subsequently lost response (not explained by any other independent concomitant medical conditions) in one blood count measurements: * Meeting again the criteria for SAA * Requirement for transfusion again for subjects who had been transfusion independent * Decrease in any of the peripheral blood counts to absolute neutrophil count \< 0.5 x10\^9/L or platelets \< 20 x10\^9/L.

Time frame:
Up to aproximately 3 years
Reported as:
Number · months
Duration of Complete Response
monthsEltrombopag
Duration of Complete ResponseNA (NA to NA)
SecondaryDuration of Overall Response

Duration of response was derived as the time from first documented and confirmed response (either CR or PR) until the time of relapse or death, whichever occurred first. Duration of response was estimated using Kaplan-Meier method. Clinical relapse was considered as the occurrence of any of the following events in a participant who had achieved a hematological response (CR or PR) but had subsequently lost response (not explained by any other independent concomitant medical conditions) in one blood count measurements: * Meeting again the criteria for SAA * Requirement for transfusion again for subjects who had been transfusion independent * Decrease in any of the peripheral blood counts to absolute neutrophil count \< 0.5 x10\^9/L or platelets \< 20 x10\^9/L.

Time frame:
Up to aproximately 3 years
Reported as:
Number · months
Duration of Overall Response
monthsEltrombopag
Duration of Overall ResponseNA (3.1 to NA)
SecondaryOverall Survival (OS)

OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. If a subject was not known to have died, survival was censored at the date of last contact. The distribution function of OS was estimated using the Kaplan- Meier method.

Time frame:
Up to approximately 3 years
Reported as:
Median · Months
Overall Survival (OS)
MonthsEltrombopag
Overall Survival (OS)NA (NA to NA)
SecondaryOverall Survival (OS) Rate

OS was defined as the time from the date of the first dose of study treatment to the date of death due to any cause. The OS rate is the estimated probability that a patient will remain event-free up to the specified time point and was obtained from the Kaplan-Meier survival estimates. If a subject was not known to have died, survival was censored at the date of last contact.

Time frame:
Week 26, Week 52 and yearly after up to 3 years
Reported as:
Number · percent probability
Overall Survival (OS) Rate
percent probabilityEltrombopag
Week 2697.2 (81.9 to 99.6)
Week 5297.2 (81.9 to 99.6)
Year 294.1 (78.3 to 95.5)
Year 390.9 (74.4 to 97.0)
SecondaryRed Blood Cells (RBC) and Platelet Transfusion-free Interval Before Week 13 and 26

Transfusion-free interval was defined as the time from most recent RBC/platelet transfusion preceding response assessment to the date of response assessment.

Time frame:
Week 13, 26
Reported as:
Mean · days
Red Blood Cells (RBC) and Platelet Transfusion-free Interval Before Week 13 and 26
daysEltrombopag
RBC transfusion-free interval - Week 1336.3 ± 25.62
RBC transfusion-free interval - Week 2698.9 ± 57.97
Platelet transfusion-free interval - Week 1334.0 ± 25.64
Platelet transfusion-free interval - Week 2697.3 ± 58.93
SecondaryPercentage of Participants Who Become RBC Transfusion Independent

Transfusion independent participants were defined as those participants who were transfusion dependent at baseline but became transfusion free for a period of ≥ 8 weeks post-baseline for RBCs.

Time frame:
From date of first dose to approximately 3 years
Reported as:
Number · percentage of participants
Percentage of Participants Who Become RBC Transfusion Independent
percentage of participantsEltrombopag
Percentage of Participants Who Become RBC Transfusion Independent86.2
SecondaryPercentage of Participants Who Become Platelet Transfusion Independent

Transfusion independent participants were defined as those participants who were transfusion dependent at baseline but became transfusion free for a period of ≥ 4 weeks post-baseline for platelets.

Time frame:
From date of first dose to approximately 3 years
Reported as:
Number · percentage of participants
Percentage of Participants Who Become Platelet Transfusion Independent
percentage of participantsEltrombopag
Percentage of Participants Who Become Platelet Transfusion Independent88.2
SecondaryTime From the Date of First Dose of Investigational Treatment to the Date of First Occurrence of Any Clonal Evolution Events

Clonal evolution events were assessed by karyotyping (G-banding) and FISH (Fluorescence in situ hybridization) targeting abnormalities including, but not restricted to chromosome 3q del,5q del, monosomy 7, trisomy 8 and those associated with SAA (Severe aplastic anemia), MDS (Myelodysplastic syndrome), AML (Acute myeloid leukemia). Time to clonal evolution was to be estimated using the Kaplan-Meier method.

Time frame:
From date of first dose to approximately 3 years
Reported as:
Number · weeks
Time From the Date of First Dose of Investigational Treatment to the Date of First Occurrence of Any Clonal Evolution Events
weeksEltrombopag
Time From the Date of First Dose of Investigational Treatment to the Date of First Occurrence of Any Clonal Evolution EventsNA (NA to NA)
SecondaryPlasma Pharmacokinetics (PK) Parameters of Eltrombopag: AUClast

AUClast is the area under the curve from time zero to the last measurable concentration sampling time. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.

Time frame:
Pre-dose, and 2, 4, 6, 8 and 24 hours post-dose on Day 14 after initial dose
Reported as:
Mean · ng*h/mL
Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: AUClast
ng*h/mLEltrombopag
Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: AUClast602000 ± 239000
SecondaryPlasma Pharmacokinetics (PK) Parameters of Eltrombopag: AUCtau

AUCtau is area under the curve calculated to the end of a dosing interval (tau) at steady-state Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.

Time frame:
Pre-dose, and 2, 4, 6, 8 and 24 hours post-dose on Day 14 after initial dose
Reported as:
Mean · ng*h/mL
Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: AUCtau
ng*h/mLEltrombopag
Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: AUCtau585000 ± 231000
SecondaryPlasma Pharmacokinetics (PK) Parameters of Eltrombopag: Ctrough

Cthrough is the pre-dose concentration at the end of dose interval. Blood samples were collected to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach. Eltrombopag was administered orally once daily with initial doses of 75mg/day for ≥ 12 years old and 37.5 mg/day for participants between ≥ 6 and \< 12 years. Doses could be adjusted based on platelet count every 2 weeks by decreasing it by 25 mg/day (12.5 mg/day, for participants below 12 years old) if the platelet count was above 200×10\^9/L. or interrupted if platelet count rose above 400×10\^9/L. In partial response participants dose could be restarted or increased to that before the decrease if platelet counts \< 30 x10\^9/L, Hb\< 90 g/L, ANC\< 0.5 x 10\^9/L or participant needed transfusion. In complete response participants dose could be restarted or increased to that before decrease if blood counts dropped to not meet CR criteria.

Time frame:
Pre-dose on day 15 after initation of eltrombopag and and pre-dose on the 15th day after each new dose up to week 26
Reported as:
Mean · ng/mL
Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: Ctrough
ng/mLEltrombopag
Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: Ctrough20200 ± 9410
SecondaryPlasma Pharmacokinetics (PK) Parameters of Eltrombopag: Cmax

Cmax is the The maximum (peak) observed plasma drug concentration after dose administration. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.

Time frame:
Pre-dose, and 2, 4, 6, 8 and 24 hours post-dose on Day 14 after initial dose
Reported as:
Median · ng/mL
Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: Cmax
ng/mLEltrombopag
Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: Cmax32500 ± 12300
SecondaryPlasma Pharmacokinetics (PK) Parameters of Eltrombopag: Tmax

Tmax is the time to reach maximum (peak) plasma drug concentration after dose administration. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.

Time frame:
Pre-dose, and 2, 4, 6, 8 and 24 hours post-dose on Day 14 after initial dose
Reported as:
Mean · hours
Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: Tmax
hoursEltrombopag
Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: Tmax5.59 ± 5.64
SecondaryPlasma Pharmacokinetics (PK) Parameters of Eltrombopag: CLss/F

CLss/F is Apparent systemic (or total body) clearance at steady state from plasma. Blood samples were collected from patients to assess the plasma concentrations of eltrombopag using a validated liquid chromatography - tandem mass spectrometry assay (LC-MS/MS) approach.

Time frame:
Pre-dose, and 2, 4, 6, 8 and 24 hours post-dose on Day 14 after initial dose
Reported as:
Mean · Liter/hour
Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: CLss/F
Liter/hourEltrombopag
Plasma Pharmacokinetics (PK) Parameters of Eltrombopag: CLss/F0.148 ± 0.0618

Adverse events

Collected over All-cause mortality: from first dose of study treatment up to 2 years after last dose including post-treatment long term follow up period up to 3.1 years approximately. Serious and Other Adverse Events: from first dose of study treatment until 30 days after last dose up to 1.1 years approximately.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eltrombopag1/36 (2.8%)14/36 (38.9%)36/36 (100%)
Eltrombopag (Post-treatment Long Term Follow-up)2/34 (5.9%)——
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventEltrombopagEltrombopag (Post-treatment Long Term Follow-up)
HyperuricaemiaMetabolism and nutrition disorders4/36—
SepsisInfections and infestations3/36—
HypokalaemiaMetabolism and nutrition disorders2/36—
Drug-induced liver injuryHepatobiliary disorders1/36—
Hepatic function abnormalHepatobiliary disorders1/36—
Herpes zosterInfections and infestations1/36—
Urinary tract infectionInfections and infestations1/36—
Alanine aminotransferase increasedInvestigations1/36—
Aspartate aminotransferase increasedInvestigations1/36—
Blood bilirubin increasedInvestigations1/36—
Most frequent other events
Showing 10 of 69
Most frequent other events
EventEltrombopagEltrombopag (Post-treatment Long Term Follow-up)
HypokalaemiaMetabolism and nutrition disorders18/36—
HyperuricaemiaMetabolism and nutrition disorders14/36—
Alanine aminotransferase increasedInvestigations13/36—
Blood glucose increasedInvestigations13/36—
PyrexiaGeneral disorders and administration site conditions12/36—
HyperbilirubinaemiaHepatobiliary disorders11/36—
Gamma-glutamyltransferase increasedInvestigations10/36—
HypoalbuminaemiaMetabolism and nutrition disorders10/36—
DiarrhoeaGastrointestinal disorders9/36—
Serum sicknessImmune system disorders9/36—

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Eltrombopag
<=18 years8
Between 18 and 65 years26
>=65 years2
Age, Continuous
Age, Continuous(years)Eltrombopag
Mean34.7 ± 18.97
Sex: Female, Male
Sex: Female, Male(Participants)Eltrombopag
Female21
Male15
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Eltrombopag
American Indian or Alaska Native0
Asian36
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

12 sites
  • Novartis Investigative Site
    Guangzhou, Guangdong 510000, China
  • Novartis Investigative Site
    Zhengzhou, Henan 450052, China
  • Novartis Investigative Site
    Nanchang, Jiangxi 330006, China
  • Novartis Investigative Site
    Changchun, Jilin 130021, China
  • Novartis Investigative Site
    Tianjin, 300020, China
  • Novartis Investigative Site
    Tianjin, 300052, China
  • Novartis Investigative Site
    Nagoya, Aichi-ken 466 8560, Japan
  • Novartis Investigative Site
    Fukuoka, Fukuoka 812-8582, Japan
  • Novartis Investigative Site
    Chuo Ku, Tokyo 104 8560, Japan
  • Novartis Investigative Site
    Seoul, 03080, South Korea
  • Novartis Investigative Site
    Seoul, 06351, South Korea
  • Novartis Investigative Site
    Kaohsiung City, 83301, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Jun 2022, 19 months.

Results were first posted in Jul 2025, 3 years 1 month after primary completion.

Of 60 phase 2 interventional studies under Anemia, Aplastic, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 104. This study's 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2020
First posted
Mar 31, 2020
StartActual
Nov 4, 2020
Primary completionActual
Jun 10, 2022
CompletionActual
Dec 6, 2024
Results first posted
Jul 17, 2025
Last update
Jan 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04328727
Responsible party
Sponsor
First posted
Mar 31, 2020
Start date
Nov 4, 2020
Primary completion
Jun 10, 2022
Completion
Dec 6, 2024
Results posted
Jul 17, 2025
Last update
Jan 13, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Eltrombopag · Thymoglobulin · Cyclosporine

Start the discussion